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Neutrophils have traditionally been thought to play only a peripheral role in the genesis of 
many autoimmune and inflammatory diseases. However, recent studies in a variety of 
animal models suggest that these cells are central to the initiation and propagation of 
autoimmunity. The use of mouse models, which allow either deletion of neutrophils or the 
targeting of specific neutrophil functions, has revealed the many complex ways these cells 
contribute to autoimmune/inflammatory processes. This includes generation of self antigens 
through the process of NETosis, regulation of T-cell and dendritic cell activation, production 
of cytokines such as BAFF that stimulate self-reactive B-cells, as well as indirect effects on 
epithelial cell stability. In comparing the many different autoimmune models in which 
neutrophils have been examined, a number of common underlying themes emerge – such 
as a role for neutrophils in stimulating vascular permeability in arthritis, encephalitis and 
colitis. The use of animal models has also stimulated the development of new therapeutics 
that target neutrophil functions, such as NETosis, that may prove beneficial in human 
disease. This review will summarize neutrophil contributions in a number of murine 





Neutrophils are the most abundant cell in the immune system. Between 1011 to 1012 
neutrophils are made each day in the human bone marrow, which comprises ~50% of the 
total cellular content of the marrow, including a large pool of fully mature cells that is poised 
for release into the circulation in response to immune challenge [1]. The role of neutrophils in 
host defense against pathogen infection has been extensively studied in many disease 
contexts. However, current research indicates that neutrophils are also involved in regulating 
other aspects of immunity. Thus it is now clear that neutrophils are both effectors and 
modulators of host immune responses [2, 3]. It is also evident that dysfunction of either of 
these neutrophil roles can lead to immune-based diseases, including a variety of 
autoimmune and autoinflammatory conditions. 
That neutrophils contribute at all to autoimmune disease pathogenesis is somewhat 
of a novel concept. Clearly, as effector cells, their contribution to tissue injury in inflammatory 
diseases, for example in immune complex-mediated diseases such as rheumatoid arthritis or 
glomerulonephritis, has long been appreciated. But the concept that neutrophil dysfunction, 
in either effector or regulatory properties, could initiate autoimmune disease is a new idea [4, 
5]. Indeed, the entire autoimmunity field is undergoing a conceptual shift with the realization 
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that dysregulation of any one of a number of innate immune cell types (especially dendritic 
cells) can be a primary driver of autoimmunity [6, 7]. Hence, determination of the 
mechanisms by which neutrophils affect adaptive immune cells is among the most dynamic 
areas of research in autoimmunity [8]. 
As effector cells, neutrophils respond to infectious pathogens through a myriad of 
molecular receptors that recognize pathogen-associated molecules. Activation of neutrophils 
through FcRs (that recognize Ig opsonized pathogens), integrins or C-type lectin receptors 
induces phagocytosis of bacteria or fungi, which in concert with stimulation of Toll-like 
receptors (TLRs), G-protein coupled receptors (such as the formyl peptide receptors) or 
various intracellular pathogen sensing molecules (such as NOD receptors), leads to 
stimulation of superoxide production as well as release of granules containing antimicrobial 
proteases and peptides [9]. Additionally, during host defense reactions neutrophils undergo 
a distinct form of cell death, referred to as NETosis, which leads to extracellular release of 
chromatin (that is often decorated with anti-microbial peptides released from granules) that 
forms a meshwork to trap extracellular pathogens [10]. Defects in any one of these effector 
functions, such as lack of integrin signaling or impairment of superoxide formation, leads to 
various forms of immunodeficiency. Importantly, these same defects in effector function can 
also contribute to autoimmune disease [11]. For example, patients with chronic 
granulomatous disease (CGD), caused by mutations in genes encoding subunits of the 
NADPH oxidase resulting in reduced or absent superoxide production, often develop 
autoimmune disease (colitis), which may be due to changes in the intestinal microbiome, 
which favor outgrowth of proinflammatory organisms. Similarly, the process of NETosis is 
now recognized as a major source of self (or auto) antigens that drive autoimmunity in 
diseases such as systemic lupus erythematous or rheumatoid arthritis [12]. Thus the 
antimicrobial role of neutrophils underlies aspects of their contribution to autoimmune 
disease.     
As regulatory cells, neutrophils have been found to modulate the function of T-cells, 
B-cells and dendritic cells, which in turn directly affects autoimmune disease pathogenesis. 
The regulatory mechanisms utilized by neutrophils includes direct effects, via the production 
of cytokines such as IL-1, IL-6, IL-10 (in murine neutrophils only), TNF and BAFF that affect 
other immune cells, as well as indirect effects, through production of superoxides or 
consumption of nutrients (amino acids or even oxygen) that limit function of neighboring 
immune cells [13, 14]. Both stimulatory and inhibitory roles for neutrophils, based on their 
ability to produce various cytokines or indirectly affect other immune cells, have been 
described in a variety of autoimmune or autoinflammatory processes. Thus, the most 
productive way to summarize the contributions of neutrophils to any given autoimmune 
disease is to review the current evidence for each disease individually. 
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This review will focus on the current evidence linking murine neutrophils to a wide 
variety of murine autoimmune and autoinflammatory disease models. We will focus on 
mechanisms by which neutrophils contribute to disease pathogenesis beyond just induction 
of tissue injury through effector mechanisms (superoxide or protease release) normally 
operative in host defense reactions. The majority of evidence will involve neutrophil depletion 
or use of genetic knockout mice in any given disease model. As the reader will see, there 
are many complex ways neutrophils are involved in autoimmune diseases that were 
previously just thought to arise from defects in T or B-cell tolerance mechanisms. 
 
 
2.  Roles for neutrophils in classical autoimmune disease models 
 
2.1.  Neutrophils in Systemic Lupus Erythematosus 
 
There is a wealth of literature demonstrating a pathogenic role for neutrophils in 
various rheumatologic diseases, in particular systemic lupus erythematosus (SLE). Most of 
this data is based on human observations, which paints a picture of abnormal neutrophils 
contributing to both inflammatory states in SLE (through production of disease inducing 
cytokines such as IL-1β or BAFF) as well as being the source of many auto-antigens in the 
disease (mainly through NETosis). However, the picture is a bit more complicated when 
these mechanisms are tested in animal models.  
Observational and in vitro experiments suggest that neutrophils contribute to human 
SLE development [15, 16]. Many SLE patients develop neutropenia during flares of active 
disease and their remaining cells show a number of functional abnormalities, such as poor 
phagocytosis and reduced superoxide production [17, 18]. A number of studies report that 
SLE patients develop an abnormal type of neutrophil referred to as a low-density granulocyte 
(LDG), which is primed in vivo to undergo NETosis. There are abundant reports linking 
NETosis to auto antigen formation and disease activity in SLE [19]. NETosis is a specialized 
form of neutrophil cell death that results in the extrusion of dense fibrillary networks of intact 
chromatin/DNA complexes that are often coated with granule proteins (such as 
myeloperoxidase (MPO), elastase or cathepsin G) and anti-microbial peptides (such as LL-
37 and others). NETosis occurs following exposure of neutrophils to pathogen-associated 
molecules (lipopolysaccharide as an example) in the setting of other inflammatory stimuli 
(such as cytokines, chemokines or immune complexes) and is believed to have evolved to 
promote host defense against pathogens by physically trapping them in the chromatin 
meshwork [20]. NETosis requires production of superoxides and H2O2 (and is reduced in 
patients with defects in the NADPH oxidase) to mobilize MPO and other granule contents to 
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the nucleus, which contribute to rapid breakdown of the nuclear membrane [21]. 
Decondensation of the nuclear chromatin is assisted by the enzyme peptidyl arginine 
deaminase (PAD) 4, which converts arginine residues on histones to citrulline to reduce 
electrostatic interactions between the histone and DNA [22]. The released chromatin 
complexes also undergo a number of additional modifications including deacetylation of 
lysine residues on histones. It is believed that this abnormal presentation of citrullinated 
and/or deacetylated chromatin in the setting of robust inflammation is the source of the 
neoantigens leading to formation of anti-dsDNA, anti-histone/chromatin and anti-citrullinated 
proteins (anti-CCP) that characterizes SLE and seropositive rheumatoid arthritis. Besides 
providing a source of neoantigens, NET contents can directly stimulate IFNα production by 
plasmacytoid dendritic cells (pDCs) [23]. Increased IFNα acts on a variety of immune cells to 
promote their activation, including feeding back on the neutrophils themselves to further 
prime additional NETosis, in the fashion of a feed forward amplification loop. Indeed, 
neutrophils from SLE patients show the same “interferon signature” of increased expression 
of IFNα-stimulated genes as well as hypomethylation (and hence activation) of IFNα 
responsive genes, which is seen in other immune cells in these patients [24]. NETs can also 
stimulate macrophages and other cells, through the NLRP3 inflammasome or the P2X7 
purinergic receptor, resulting in the release of IL-1 and IL-18, further exacerbating the 
inflammatory state in SLE patients [25]. Finally, neutrophils from SLE patients with active 
disease also produce high amounts of BAFF, which directly acts on autoreactive B-cells to 
support their survival and proliferation and hence contribute to autoimmune antibody 
production [26]. 
Direct validation of these mechanisms in mouse models, however, is not completely 
supportive and tends to give a mixed picture of neutrophils in SLE pathogenesis. The most 
direct experimental evidence of a role for neutrophils in driving systemic autoimmunity 
comes from chronic neutrophil depletion experiments [13, 14]. Coquery et al. found that 
neutrophil depletion, achieved by every other day injection of the anti-Ly6G depleting mAb 
for four weeks, led to a reduction in auto-antibody titers, serum IFN, serum BAFF, T cell 
activation as well as the number of splenic germinal center B cells and plasma cells in the 
autoimmune prone B6.Faslpr/JTnfrsf17-/- strain. In this strain, high production of BAFF by 
neutrophils may help drive the selection and survival of autoimmune B cell clones that 
produce self-reactive antibodies, such as anti-double stranded DNA antibodies. The 
interplay of BAFF, T cells and IFN has also been suggested in the lyn-/- model of 
autoimmunity [27]. While chronic depletion of neutrophils is fraught with potential 
complications and is technically challenging, this is one of the few direct methods to show 
that neutrophils are involved in the development of self-reactive lymphocytes. 
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Less direct approaches have mainly involved modulation of neutrophil NETosis. In 
the New Zealand Black/New Zealand White (NZB/W) mouse model of systemic 
autoimmunity, deposition of NETs in kidneys and skin build up with disease progression, and 
in turn drive IFNα production [28]. Similar accumulation of tissue deposits of NETs and 
formation of autoantibodies that recognize NET components such as anti-microbial peptides 
(CRAMP, the murine analog of human LL-37) have been reported in the related New 
Zealand mixed 2328 (NZM) model of murine lupus [29]. Like humans, neutrophils from NZM 
mice undergo increased NETosis in vitro. Neutrophils from a third animal model of SLE, the 
MRL/lpr model which results from a mutation in the Fas gene leading to reduced immune 
cell apoptosis, also have been reported to undergo increased spontaneous NETosis [30]. In 
both the NZM and the MRL/lpr, blocking NET formation by treatment of mice with PAD4 
inhibitors reduced systemic disease development [29, 30]. Treatment with the PAD inhibitors 
Cl-amidine or BB-Cl-amidine leads to reduced tissue deposition of NETs, reduced 
autoantibody levels, reduced nephritis and reversal of IFNα signature in both models. These 
inhibitors also reduced lipid oxidation in NZM mice, which correlated with improved 
endothelial and cardiovascular function in this SLE model [31].  
These seemingly positive results are contradicted by the observation that blocking 
NETosis in MRL/lpr mice by inhibition of NADPH oxidase function (by crossing MRL/lpr mice 
to Nox2 deficient animals) in fact leads to exaggerated systemic autoimmunity and 
aggravated kidney injury [32]. Indeed, Schauer et al. have suggested that NETs may provide 
an anti-inflammatory function through degradation of cytokines and chemokines within 
inflammatory sites [33]. This study confirms that blockade of NETosis by genetic deficiency 
in one of the subunits of the NADPH oxidase (in this case the p47phox protein) leads to hyper-
inflammatory responses which were reversed by direct transfer of pre-formed NETs into the 
inflammatory site. Part of this apparent paradox may be explained by other important 
functions of the neutrophil NADPH oxidase in systemic autoimmunity, besides just 
stimulating NETosis. Huang et al. recently confirmed that both neutrophil depletion and 
blockade of neutrophil NADPH oxidation function leads to exacerbated systemic 
autoimmunity in the NZB/W model [13]. These authors correlated the reduced levels of 
superoxide production, using in vitro approaches, with increased production of IFNα and 
IFNβ from pDCs, as well as increased IFNγ from NK cells, that together drove inflammation 
and promoted autoantibody production. In contrast, blockade of mitochondrial ROS 
production (which is obviously much less robust than ROS production through the NADPH 
oxidase) has recently been reported to be sufficient to block NETosis in vitro as well as 
reduce disease severity and IFNα responses in MRL/lpr mice [34]. Hence, using NADPH 
ROS blockade to test the role of NETosis in mouse models may be complicated by the fact 
that both T-cells and NK cells will over produce IFNγ and hence drive inflammation and 
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autoimmunity. Instead, perhaps only blockade of mitochondrial production of ROS is 
sufficient to validate the role of NETosis in murine SLE models. 
A third approach to modulate NETosis effects in animal models has involved 
alterations in histone modifications during disease development. Various studies have 
investigated the significance of histone acetylation in SLE neutrophils. Hypoacetylation of 
histones H3 and H4 has been found in splenocytes from MRL/lpr mice [35]. Treatment of 
MRL/lpr mice with HDAC inhibitor trichostatin A reverses the hypoacetylation of histones H3 
and H4, which correlates with an improved disease phenotype. In addition, mice deficient in 
histone acetyl transferase p300, resulting in hypoacetylation of H3 and H3 develop a 
systemic autoimmune disease similar to SLE [36]. These studies suggest that modulation of 
histone acetylation may ameliorate the pathogenic potential of neutrophil NETs. 
The role of neutrophil myeloperoxidase (MPO) in systemic autoimmunity has also 
been somewhat controversial. The proinflammatory effect of MPO, through production of 
oxidants and in promotion of NETosis, would seemingly be a major contributor to disease 
pathogenesis [37]. Yet MPO-knockout mice develop increased autoimmunity and end organ 
damage in the pristane model of lupus [38]. The mechanism for this apparent paradox is 
unclear, but since the pristane treated MPO-deficient mice developed high levels of IFNγ 
producing CD4+ T-cells, it is possible that the loss of MPO releases a brake on T-cell 
expansion during inflammatory states. Similar to the effect of ROS, it has been suggested 
that neutrophil-derived MPO limits T-cell mediated inflammation through an effect on DC 
priming [39]. This is another example of how animal models of SLE can produce somewhat 
unexpected findings that illuminate complex regulatory loops involving neutrophil effector 
functions in autoimmunity. 
 
2.2.  Models of vasculitis 
 
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a 
group of inflammatory vasculitides characterized by the development of autoantibodies that 
recognize neutrophil granule enzymes MPO and proteinase-3 (PR3). ANCAs bind to 
cytokine-primed neutrophils, leading to neutrophil activation (in part through simultaneous 
binding to both MPO/PR3 and Ig Fc receptors), degranulation, cytokine release and ROS 
production [40, 41]. In particular, ANCA-stimulated neutrophils release large amounts of 
BAFF, which may support further expansion of autoreactive B cells in this disease [42]. 
ANCA-stimulated neutrophils also undergo NETosis, which may exacerbate tissue injury; 
indeed, both free circulating and kidney deposits of MPO-DNA complexes have been 
reported in patients with inflammatory vasculitis [43]. The production of NETs by ANCA-
stimulated neutrophils can also prime DCs to present additional MPO and PR3 peptides to 
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further drive autoimmunity in this disease. In mice, transfer of myeloid DCs treated with NET 
components into naïve animals leads to the development of ANCA antibodies and systemic 
vasculitis [44]. A mouse model of ANCA-associated vasculitis has been established by 
sensitizing MPO-deficient mice with MPO then transferring their splenocytes or purified IgG 
to healthy animals, which results in systemic vasculitis and necrotizing glomerulonephritis 
[45]. Using both chimeric mice and neutrophil-depletion approaches, it has been 
demonstrated that the cellular target for the transferred ANCA is indeed the neutrophils in 
the recipient mouse [46]. The role of neutrophil Fc receptors has been tested in this model 
through transfer of anti-MPO antibodies into FcR deficient mice. As expected, mice lacking 
the inhibitory FcγRIIB receptor develop much more fulminant disease following transfer of 
anti-MPO antibodies [47]. A similar, though less pathogenic model of anti-PR3 ANCA has 
also been described, again by immunizing PR3/neutrophil elastase deficient mice with 
recombinant murine PR3 [48]. A monoclonal anti-PR3 ANCA antibody model has been used 
in isolated rat lungs to show that activation of the neutrophil NADPH oxidase is a major 
mediator of tissue injury [49]. However, in the anti-MPO antibody-mediated disease model, 
Schreiber et al. have recently reported just the opposite – mice genetically deficient in 
NADPH oxidase activity (either Nox2 or p47phox deficient animals) actually developed more 
severe vasculitis and glomerulonephritis following challenge with anti-MPO serum [50]. 
These authors found that the NADPH oxidase-deficient neutrophils over produced IL-1β 
following anti-MPO antibody challenge and that IL-1β-receptor blockade protected recipient 
mice from severe glomerulonephritis following anti-MPO challenge. Doubly deficient Nox2 
and caspase-1 mutant mice were also resistant to anti-MPO mediated disease. Again, these 
somewhat surprising results in mouse models illustrate the complex interactions between 
different neutrophil effector functions in autoimmune diseases.  
 
2.3.  Autoimmune arthritis models  
 
The contribution of neutrophils to autoimmune arthritis has been extensively studied 
in a variety of mouse models. In these models, it has been found that neutrophils contribute 
to both the initiation (or establishment) of disease as well as to the effector (or tissue injury) 
phase of disease. Various mouse models mimic these different stages of autoimmune 
arthritis pathogenesis.  
The most widely used model for studying the complete disease process is the 
collagen-immunization model [51]. This model includes both the priming or initiation phase of 
the disease, which requires T- and B-cell responses leading to production of pathogenic anti-
collagen and other antibodies, as well as the effector phases, which involve recruitment of 
neutrophils to the inflamed joint, leading to cellular activation with cartilage and bone injury. 
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In human rheumatoid arthritis, many of the autoantibody specificities are directed against 
citrullinated antigens (such as citrullinated collagen, fibrinogen, vimentin or anti-histone 
antibodies), which are thought to be induced by release of PAD4 during neutrophil NETosis 
[52]. Indeed, blocking PAD4 activity with Cl-amidine decreases clinical disease in the 
collagen-induced model by ~50% [53]. Disease reduction in the Cl-amidine treated mice is 
also associated with reduced production of anti-citrullinated antibodies, directly suggesting 
that neutrophil NETosis is contributing to the antigenic stimulation in this model. This is 
supported by previous studies showing that depletion of neutrophils or reduction in 
neutrophil production through genetic deficiency of G-CSF (or antibody blockade of G-CSF) 
also blocks disease development in the collagen-induced arthritis model [54]. Besides 
providing a source of antigens in the priming phase of arthritis, neutrophils are also required 
for deposition of the preformed antibodies along the articular surfaces of the joints. In mice, 
deposition of anti-collagen antibodies in the joint, following direct injection into naïve mice, 
requires neutrophils and neutrophil activation by immune complexes [55]. Similar results 
have been reported in the passive arthritis KxB/N model (see below) suggesting that 
neutrophil activation directly influences vascular permeability which allows deposition of 
immune complexes, such as anti-collagen antibodies, in the earliest stages of disease [56].   
The other widely used model of autoimmune arthritis in mice is the passive serum 
transfer model referred to as the K/BxN model. This model reflects only the effector phase of 
the disease as it works by transferring pathogenic IgG-containing serum into naïve mice, 
which results in severe, but transient arthritis due to immune complex deposition in the joint 
[57]. The pathogenic serum is formed in transgenic K/B mice crossed onto the non obese 
diabetic (NOD) background; the resulting mice develop progressive erosive arthritis due to 
formation of IgGs that recognize glucose-6-phosphate isomerase (anti-GPI) along the 
cartilaginous surface of the large joints in the feet. Transfer of the serum from K/BxN mice to 
any other mouse produces joint inflammation. Disease in recipient mice is dependent on 
FcR signaling pathways in neutrophils, suggesting that recognition of joint immune 
complexes occurs by circulating cells [56, 58]. Neutrophils amplify their own recruitment to 
the inflamed joint through the coordinated production of chemoattractants, such as LTB4 as 
well as cytokines such as IL-1β, the latter of which acts on synovial cells to stimulate 
additional neutrophil recruitment [59, 60]. One of the synovial-derived cytokines involved is 
G-CSF, which is also required for neutrophil recruitment in the K/BxN serum transfer arthritis 
model [61]. Neutrophil production of IL-17 has also been implicated as an amplifier of 
arthritis in this model [62]. As mentioned above, neutrophil activation following recognition of 
early immune complexes in the joint may also lead to changes in vascular permeability, 
which further promotes IgG deposition [63]. As expected, PAD4 deficiency does not affect 
the K/BxN serum transfer arthritis model, since the model reflects only the effector phase of 
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the disease [64]. Interestingly, mice lacking the p47phox subunit of the neutrophil NADPH 
oxidase develop much more severe arthritis in the K/BxN serum transfer model (as well as in 
a passive anti-collagen antibody transfer model) [65, 66]. The mechanism of this somewhat 
surprising observation is unclear, but may involve ROS-mediated suppression of other 
signaling pathways or chemoattractant (LTB4) release by neutrophils, or as suggested in 
systemic inflammatory disease, the ability of neutrophil-derived ROS to affect other immune 
cells, such as Tregs [67]. Hence, even in the effector phases of inflammatory arthritis, 
neutrophils are critical for regulating the activity of other immune and synovial cells, which 
act in concert to amplify the inflammatory cascade.  
 
 
3.  Neutrophils in neuroinflammatory disease models 
 
3.1.  Experimental autoimmune encephalomyelitis (EAE)  
 
The mouse EAE model has been used extensively to replicate the autoimmune 
pathogenesis in human multiple sclerosis [68]. EAE is initiated by immunization of mice with 
myelin protein or peptides, which leads to development of self-reactive CD4+ Th17 cells that 
infiltrate the CNS leading to demyelination and neuronal injury. Myeloid cell infiltration into 
the CNS is a major component of the EAE model and is also seen in human multiple 
sclerosis lesions [69]. Indeed, early reports demonstrated that antibody-mediated depletion 
of neutrophils results in a dramatic reduction in EAE pathology in both the brain and spinal 
cord [70], consistent with the view that activation of neutrophil effector function is a major 
source of tissue injury in this model. Using adoptive transfer methods, Carlson and 
colleagues found that CXCR2 expression on neutrophils is required for their recruitment into 
the CNS in the EAE model, suggesting that disease was initiated by other cells (such as 
CNS macrophages or Th17 cells) which produced CXC chemokines (mainly CXCL1 and 
CXCL2 in mice, the analogues of CXCL8 or IL-8 in humans) that allowed neutrophil 
recruitment and subsequent tissue injury [71]. As in other autoimmune models, production of 
GM-CSF by T-cells and stromal cells in the CNS has also been implicated as a major factor 
in neutrophil recruitment in EAE [72]. Similar results have been reported in mice lacking the 
G-CSF receptor, which mount poor neutrophil responses during EAE [73]. Most of these 
results support the traditional notion that neutrophils act in the effector phase of EAE to 
mediate tissue injury. Interestingly, neither MPO or neutrophil elastase seem to be involved 
in the development of neural injury, since EAE proceeds normally in MPO knockout mice 
and inhibitors of neutrophil elastase do not affect disease progression [74]. However, hyper-
activation of neutrophils, through myeloid-specific deletion of the inhibitory factor SOCS3, 
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results in a severe form of EAE in myelin-immunized mice that is characterized by high 
levels of neutrophil recruitment to the CNS and overproduction of chemokines (mainly 
CXCL2) and inducible NO [75]. A potential suppressive effect of neutrophil-derived nitric 
oxide on T-cell proliferation in response to myelin protein has also been described in EAE, 
similar to in vitro findings in systemic autoimmunity [76]. These observations point to a 
complicated interaction between neutrophils and other immune cells during the effector 
phases of EAE. 
There is growing recognition that neutrophils may also contribute to the early phases 
of neuroinflammation in the EAE model [77]. Careful observation of these early events in 
EAE using two photon imaging methods has shown that neutrophils can directly affect the 
blood/brain barrier and promote early vascular permeability [78]. Using lysM-eGFP marked 
cells, Aube and colleagues could visualize the very early recruitment of neutrophils to the 
neurovasculature within one day following disease initiation. This rapid influx of neutrophils 
correlates with increases in vascular permeability (determined by dye leakage) in the CNS 
but precedes the onset of clinical neurologic symptoms in the mice. Neutrophil depletion 
prevented the early disruption of the blood/brain barrier in immunized mice, correlating with 
reduced clinical disease development. This early role for neutrophils in promoting vascular 
permeability during neuroinflammation is reminiscent of a similar role proposed for these 
cells during autoantibody-mediated arthritis [56]. The mechanisms and mediators by which 
neutrophils promote early changes in vascular permeability in inflammatory responses 
remain to be defined. 
Neutrophils have also been found to promote the maturation of microglia and 
monocytes/macrophages into fully mature, MHC class II-expressing antigen presenting cells 
during EAE [74]. Careful examination of the CNS inflammatory cell infiltrate in EAE mice 
following neutrophil depletion suggests that the major cell type affected appears to be 
inflammatory monocytes and CD11c+ dendritic cells, which are reduced in number and 
manifest reduced expression of co-stimulatory molecules needed for efficient antigen 
presentation. Hence, progressive diminution of myelin-reactive T-cells within the CNS could 
also contribute to reduction of disease in neutrophil-depleted mice. Again, this neutrophil-




4.  Neutrophils in autoimmune uveitis 
 
The uvea is the middle layer of the eye, consisting of the iris, the ciliary body and the 
choroidea. Inflammation of this layer is associated with several autoimmune diseases (e.g. 
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ankylosing spondylitis, Behcet’s disease, etc.) and is the leading cause of blindness in 
Western societies [79]. Experimental autoimmune uveoretinitis (EAU) can be triggered in 
mice by immunization with the interphotoreceptor retinoid-binding protein (IRBP). Wild type 
mice develop leukocytosis with marked neutrophilia in EAU that correlates with increased G-
CSF levels in the serum and the eye [79]. In the absence of G-CSF, inflammation and 
neutrophil accumulation is decreased. In line with this finding, anti-G-CSF antibody treatment 
also suppresses the intraocular inflammation [79]. As in other autoimmune models, the 
potential roles of G-CSF in EAU include mobilization of neutrophils from the bone marrow, 
triggering neutrophil-attracting chemokines from tissue resident cells and upregulating the 
chemokine receptor CXCR2 on the cell surface of neutrophils [79].  
In a second model of autoimmune uveitis, inflammation is triggered by the intraocular 
injection of ovalbumin into DO11.10 transgenic mice whose T cells are engineered to 
recognize ovalbumin [80]. Here, intraocular anti-IL-17 treatment decreases neutrophil influx, 
probably by suppressing the production of neutrophil-attracting chemokines like CXCL2 [80]. 
The involvement of neutrophil-derived ROS and/or nitric oxide in the early phases of 
autoimmune uveitis remains to be investigated. 
 
 
5.  Neutrophils in dermatologic disease models 
 
5.1.  Models of autoimmune bullous diseases 
  
Two major autoimmune bullous skin diseases have been modeled in mice: bullous 
pemphigoid (BP) and epidermolysis bullosa acquisita (EBA). BP results from development of 
pathogenic autoantibodies recognizing hemidesmosomal proteins BP180 or BP320, while 
EBA is caused by development of autoantibodies recognizing collagen VII [81]. Deposition of 
these autoantibodies along the dermal/epidermal border produces a neutrophil-dominant 
inflammatory reaction that leads to separation of the epidermis from the dermis, and blister 
formation. These diseases can be mimicked in mice by passive transfer of anti-BP180 or 
anti-collagen VII antibodies, raised in rabbits. Liu and colleagues have carefully dissected 
the role of neutrophils in the BP model, showing that recognition of skin immune complexes 
by neutrophil FcRs is required for release of proteases (in particular, neutrophil elastase, but 
also matrix metallopeptidase-9) that in turn degrade BP180, generating peptides that attract 
additional neutrophils to amplify the inflammatory process [82]. In contrast to immune-
complex arthritis models, C5a receptor signaling is not needed on neutrophils, but instead is 
required on tissue resident mast cells to initiate the skin disease [83]. Hence, the chemokine 
receptors involved in neutrophil recruitment/activation in this model remain unclear. In the 
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EBA model, activation of the neutrophil NADPH oxidase leading to ROS production has 
been implicated as critical mediator of tissue injury [84]. To model both the initiation phase 
and the effector phase of these diseases, models in adult animals relying on extensive 
immunization with BP180 or collagen VII have been established. In the immunization 
models, neutrophil depletion is partially effective in reducing disease [85]. Interestingly, in the 
immunization-induced EBA model, chronic depletion of neutrophils (or use of GM-CSF 
knockout mice) leads to reduced autoantibody titers, with reduced skin inflammation [86]. 
This suggests that neutrophils may also contribute to the initiation of autoantibody production 
as well as participating in the effector phase of the disease. Clearly, the roles of NETosis 
and various neutrophil-produced chemokines/cytokines need to be determined in these 
blistering skin diseases. 
 
5.2.  Psoriasis 
 
Psoriasis is a persistent inflammatory skin disease that is driven in large part by T-
cell activation leading to chronic IL-17 production. Neutrophilic inflammation is also a major 
aspect of active psoriatic lesions resulting in accumulation of neutrophil chemokines and 
chemoattractants. Accumulation of pDCs, which secrete large amounts of IFNα, has also 
been reported in xenograft models of psoriasis [87]. Psoriasis in animal models has typically 
been modeled by topical application of imiquimod (a TLR7 and adenosine receptor agonist) 
that induces chronic skin inflammation, which histologically mimics human psoriasis, 
including infiltration of T-cells, expression of IL-17 and IFNα along with the development of 
neutrophil microabscesses in the epidermis [88-90]. However the model is complicated by 
the fact that some preparations of imiquimod may stimulate inflammasome activation 
independently of TLR7 signaling [91]. Neutrophil depletion in mice reduces the inflammatory 
response to topical imiquimod application [92]. Neutrophil depletion also reduces skin 
inflammation in the fsn/fsn flaky-skin mouse model of psoriasis, which contain a 
homozygous recessive mutation in the Ttc7 gene that broadly affects immune cells [93, 94]. 
Mice deficient in the neutrophil chemoattractant receptor BLT1, which recognizes LTB4, are 
also strongly protected from imiquimod-induced inflammation [92]. This same study 
implicated neutrophil production of LTB4 and IL-1β as major amplifiers of the skin 
inflammatory response, similar to the role these neutrophil products play in autoimmune 
arthritis models. Indeed, a number of neutrophil-derived products have been implicated in 
amplifying inflammation in the imiquimod psoriasis model. Shao et al have found that 
lipocalin-2, which is an antimicrobial peptide, is strongly expressed is psoriatic lesions and its 
neutralization by mAb treatment alleviates inflammation in the imiquimod model [95]. 
Lipocalin-2 is highly produced by neutrophils in psoriatic skin and can activate neutrophils as 
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well as act as a neutrophil chemoattractant.  Recently, Henry et al. reported that neutrophil-
derived proteases (cathepsin G, elastase and PR3) promote the cleavage of the IL-1 related 
cytokine IL-36 in a xenograft model of psoriasis [96]. This finding is particularly intriguing 
because one of the most virulent forms of human pustular psoriasis is known to be caused 
by mutations in the IL-36 receptor antagonist, suggesting that dysregulated IL-36 signaling is 
particularly proinflammatory in the skin [97]. Similarly, mice deficient in IL-36 receptor 
antagonist are hyper-responsive to imiquimod treatment, while IL-36 receptor knockout mice 
are protected [98]. Additionally, neutrophil-derived cytokines can act on skin keratinocytes to 
promote further production of IL-36, which in turn drives more neutrophil recruitment in a 
self-amplifying loop of inflammation [99]. Such neutrophil-keratinocyte crosstalk is yet 
another example of the regulatory role of neutrophils in autoimmune/inflammatory diseases. 
 
 
6.  Neutrophils in autoimmune endocrine conditions 
 
6.1.  Type 1 diabetes mellitus 
 
Type 1 diabetes mellitus is a T cell-mediated autoimmune disorder that requires 
insulin replacement therapy for the entire life of patients suffering from the disease. The 
major mouse model for this disease is the non obese diabetic (NOD) model; these mice 
develop an inflammatory autoimmunity against their pancreatic islet (insulin producing) β-
cells [100]. Early in the disease process the pancreatic islets of NOD mice develop a 
transient influx of neutrophils [101]. This influx is reduced by pharmacological blockade of 
the chemokine receptor CXCR2 [102]. The main chemokines that mediate neutrophil arrival 
seem to be CXCL1 and CXCL2, produced by pancreatic macrophages and insulin-secreting 
β-cells [102]. Macrophages can trigger CXCR2-ligand production by β-cells through release 
of IL-1β [102]. Additionally, pancreatic neutrophils can cooperate with CD5-positive B-1a 
cells to trigger IFNα production by pDCs, as observed in other autoimmune models [101]. 
The B-1a cells produce anti-DNA autoantibodies that trigger neutrophil activation and NET 
formation through activating Fcγ receptors [101]. This leads to the release of the 
antimicrobial peptide CRAMP, which in turn binds to the Ig-bound DNA to form complexes 
that further potentiate pDC activation through TLR9/Fcγ signaling pathways [101]. 
Importantly, early blockade of neutrophil accumulation attenuates the onset of diabetes 
mellitus in mice by decreasing the number of effector CD8-positive T cells in the pancreas 
[101]. These results suggest that interactions between neutrophils, B-lymphocytes and pDCs 
play an important role in initiating the destructive anti-islet cell autoimmunity that leads to 
diabetes in the NOD mouse model. 
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6.2.  Autoimmune thyroiditis   
 
Autoimmune thyroiditis is one of the most prevalent autoimmune diseases in the 
world. Granulomatous experimental autoimmune thyroiditis (G-EAT) can be triggered by 
repeated intravenous injection of thyroglobulin in DBA/1 mice [103]. Following immunization 
neutrophils migrate in huge numbers to the thyroid glands, in response to upregulation of 
CXCL1 and CXCR2 in the inflamed tissue [104]. As in the NOD mouse model, this early 
arrival of neutrophils may help prime development of both T-cell and B-cell autoimmunity in 
the G-EAT model.  
 
 
7.  Roles for neutrophils in non-classical autoinflammatory-like disease models 
 
Autoinflammation and autoimmunity share many common features such as chronicity 
or self-destruction by immune cells; however, autoinflammatory conditions lack 
autoantibodies, autoreactive lymphocytes and MHC allele-correlations. According to the 
Immunological disease continuum view, there is a smooth transition from classical 
autoinflammatory diseases like the monogenic Familial Mediterranean Fever (FMF) to 
classical autoimmune diseases like systemic lupus erythematosus (SLE) with intermediate 
conditions sharing several aspects with autoinflammatory syndromes [105]. Such polygenic 
diseases include gout and inflammatory bowel diseases (Crohn’s disease and Ulcerative 
colitis), all of which are known to have dysregulated NOD-like receptor (NLR) signaling as a 
central mechanism for their pathogenesis [105, 106]. 
 
7.1.  Neutrophils in gout 
 
Gout is a relatively common autoinflammatory-like arthritis that is characterized by 
recurrent painful attacks often associated with extra-articular manifestations such as kidney 
stones and nephropathy. The initial molecular event is the deposition of monosodium urate 
(MSU) crystals in the joints that triggers neutrophil influx [107]. In the air-pouch model of 
gouty arthritis, subcutaneous pouches are made by the injection of sterile air that leads to a 
synovial-like barrier after seven days [108]. Upon MSU crystal injection, resident cells are 
activated, releasing chemokines such as CXCL1, resulting in rapid recruitment of neutrophils 
to the air pouch. Mice lacking the CXCL1 receptor (CXCR2) manifest a significant block in 
neutrophil recruitment in the MSU air-pouch model [108]. Furthermore, S100A8 (MRP8) and 
S100A9 (MRP14), two important neutrophil-derived factors have also been shown to 
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mediate neutrophil accumulation in the MSU crystal-injected air-pouch, since direct injection 
of these proteins will stimulate neutrophil influx, whilst their neutralization using anti-
S100A8/9 blocking antibodies prevents neutrophil accumulation in the MSU air pouch [109, 
110]. The MSU crystals initiate inflammation by activating the NALP3 inflammasome in 
tissue resident macrophages, leading to robust IL-1β production [111]. Mice deficient in key 
inflammasome components (ASC, an inflammasome adaptor protein, or Caspase-1, that 
cleaves pro-IL-1 to mature IL-1β) show a significantly impaired neutrophil influx in MSU-
induced peritonitis [111]. Similarly, IL-1 receptor (IL-1R)-deficient mice also fail to 
accumulate neutrophils in the peritoneal cavity following MSU injection [111]. Moreover, 
antibody-mediated blocking of IL-1R or use of the IL-1R antagonist Anakinra also markedly 
impairs MSU-mediated neutrophil influx [112]. In line with previous findings, NLRP3, ASC, 
Caspase-1, IL-1β, IL-1R are also important in MSU crystal-induced articular inflammation 
and hyper-nociception [113]. In this model, neutrophil accumulation is also dependent on 
CXCR2 and the release of CXCL1 is dependent on the NALP3/NLRP3 inflammasome. 
It is an intriguing question how the attacks of gouty arthritis resolve spontaneously as 
self-limiting inflammatory reactions. One theory suggests that uptake of apoptotic debris by 
neutrophils stimulates their production of TGFβ1, which has the potential to downregulate 
proinflammatory neutrophil functions like superoxide production in the MSU crystal-induced 
peritonitis model [114]. On the other hand, MSU crystals have been shown to trigger NET 
release and the aggregation of NETs; mice with a loss of function mutation in p47phox, which 
blocks NETosis, develop chronic and aggravated inflammation in the MSU model [33]. 
These authors suggest that robust neutrophil recruitment induced by MSU crystal injection 
leads to the formation of densely packed NETs, which are laden with proteases that degrade 
proinflammatory chemokines and cytokines, thus actually limiting further inflammatory cell 
recruitment [33]. In line with this finding, ‘NETosis-deficient’ p47phox mutant mice show 
elevated cytokine levels in the MSU-containing air pouches, which is decreased by the 
injection of aggregated NETs, isolated from wild type mice, in the pouch. An additional 
limiting mechanism could be that C5a triggers the release of neutrophil microvesicles that in 
turn decrease the priming effect of C5a on inflammasome activation and IL-1β production, 
resulting in a suppressed neutrophil accumulation [115]. 
 
7.2.  Neutrophils in experimental colitis 
 
Inflammatory bowel diseases (IBD) cause tremendous burden to patients. The role of 
neutrophils in experimental colitis models is controversial as some data show their 
contribution to mucosal damage, while others report beneficial effects [116]. In the dextran 
sulfate sodium (DSS) induced colitis model, the lack of the chemokine receptor CXCR2 
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suppresses neutrophil infiltration to the gastrointestinal tract thus reducing mucosal injury 
[117]. In line with this finding, the blockade of CXCR2 also results in an attenuated 
inflammation in DSS experimental colitis [118]. In the trinitrobenzene sulfonic acid (TNBS) 
colitis model (which tends to produce a more chronic inflammatory process than DSS), 
treatment with a blocking anti-CXCL1 antibody or a pharmacologic CXCR2 antagonist also 
significantly reduces inflammation, neutrophil influx, intestinal myeloperoxidase activity, IL-
1β, CXCL1 and CXCL2 levels [119]. It is intriguing that while the early phases of the TNBS-
induced acute colitis depend on the CXCR2 receptor, later phases seem to be CXCR2-
independent, suggesting, as in other inflammatory diseases, that neutrophils affect early 
phases of the inflammatory response potentially by altering vascular permeability [120]. 
Blocking integrin β2 (CD18) also results in a significant decrease of myeloperoxidase activity 
and the concomitant mucosal permeability in the TNBS-induced acute colitis model, pointing 
again at a pathological role for neutrophils in experimental colitis [121, 122]. 
In contrast, treatment with antibodies against L-selectin or neutrophil-depleting 
antibodies, actually aggravates disease severity in TNBS-induced colitis, indicating a 
potential protective role for neutrophils during pathogenesis [123]. Campbell et al. recently 
hypothesized an interesting mechanism by which neutrophils may be protective in intestinal 
inflammation [124]. As in other disease models, these authors noted that Nox2‒/‒ mice 
displayed dramatically enhanced inflammatory responses in the TNBS colitis model. Genetic 
deficiency of the p47phox subunit of the NADPH oxidase also results in increased 
inflammation in the DSS colitis model [125]. In parallel with these observations, humans 
suffering from Chronic granulomatous disease are more susceptible to inflammatory bowel 
diseases [126]. Campbell et al. noted that the intestinal epithelial cells in these models 
upregulate a number of hypoxia-dependent protective genes, which are transcriptional 
targets of the hypoxia-inducible factor (HIF) transcription factor [124]. Stable expression of 
HIF can be visualized in the intestinal epithelia during colitis using a reporter mouse model. 
These authors postulated that during epithelial transmigration, activation of their NADPH 
oxidase causes neutrophils to consume large amounts of oxygen leading to a localized 
hypoxia that affects the transcriptional response of neighboring epithelial cells leading to 
stable expression of HIF. Indeed, this can be directly demonstrated in co-culture 
experiments with neutrophils and epithelial cells – induction of superoxide production in 
neutrophils leads to upregulation of HIF in the epithelial cells. Depletion of neutrophils 
reduces HIF gene expression in epithelial cells during TNBS colitis. Moreover, 
pharmacological stabilization of HIF with AKB-4924 [127] dramatically increases HIF 
expression in the epithelia of Nox2-/- mice and significantly improves inflammatory resolution 
during TNBS colitis. This neutrophil-epithelial cell crosstalk, through localized consumption 
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of oxygen, points to yet another mechanism by which neutrophil functions indirectly affect 
immune responses in disease models.  
 
7.3.  Alzheimer’s disease  
 
Though not strictly an autoimmune process, it has long been recognized that 
neuroinflammation is a major component of neurodegenerative diseases such as 
Alzheimer’s disease. The major causative factor of Alzheimer’s disease is the accumulation 
of beta-amyloid in plaques and aggregates associated with neurodegeneration. These beta-
amyloid protein aggregates have been shown to activate monocytes and microglia to 
promote neuroinflammation [128]. Indeed, migration of neutrophils into beta-amyloid plaques 
has been observed in mouse models of Alzheimer’s disease using two photon microscopy 
techniques. In the 5XFAD mouse (which overexpresses mutated forms of human amyloid 
precursor protein (APP) and presenilin 1 (PS1)), Baik et al. were able to visualize migration 
of adoptively transferred neutrophils into amyloid plaques [129]. These results were 
expanded in a recent study by Zenaro et al., who reported that in both the 5XFAD and the 
3XTg AD mouse (which expresses mutated forms of PS1, APP and tau protein), neutrophil 
adhesion and intraluminal crawling is observed along neurovascular structures adjacent to 
amyloid plaque deposits [130]. The adhesion of neutrophils to the neurovasculature in these 
Alzheimer’s mouse models is dependent on expression of the leukocyte integrin LFA-1 by 
neutrophils, which recognize increased ICAM-1 present on vascular endothelium, similar to 
neutrophil recruitment in virtually all other inflammatory responses [131]. Most importantly, in 
these Alzheimer’s models, neutrophil infiltration of the brain begins before the onset of 
cognitive decline and peaked around the time that memory loss is first observed. Indeed, 
depletion of neutrophils from the blood of 3XTg AD mice restored cognitive function in two 
behavioral tests of learning and memory. Similarly, blocking neutrophil recruitment into the 
brain in these models by using blocking anti-LFA1 antibodies also reduced cognitive deficits 
and neuropathology in the mice. These exciting and unexpected results suggest that 
neutrophils may play additional, unanticipated roles in neurodegenerative disease (perhaps 
regulating vascular permeability as in EAE models). Clearly, this is an area of exciting 
research [132]. 
 
7.4.  Neutrophilic dermatosis  
 
The neutrophilic dermatoses are a spectrum of skin inflammatory disorders, 
characterized by robust neutrophilic inflammation of the skin, in the absence of obvious 
infection. Often these diseases are associated with other autoimmune or inflammatory 
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processes, such as inflammatory bowel disease [133, 134]. A variety of neutrophil functional 
defects, in chemotaxis, phagocytosis and other functions have been linked to various 
neutrophilic dermatoses, but as yet there is little molecular understanding of these 
processes. Some monogenic forms of neutrophil-mediated skin inflammation have been 
described, such as the PAPA syndrome, which results from mutations in the PSTPIP-1 gene 
leading to dysregulated IL-1β and IL-18 production that drive the inflammatory response 
[135, 136]. A number of mouse models of various autoinflammatory disorders, mainly 
resulting from inflammasome dysregulation leading to excessive IL-1 production, have 
features of neutrophilic dermatoses [137], however, none of these are particularly neutrophil 
specific. Recently, Abram et al. reported the serendipitous generation of a mouse model of 
sterile neutrophilic skin inflammation in a mouse model with hyperactive β2 integrin signaling 
restricted to neutrophils [7]. These mice lack the inhibitory tyrosine phosphatase SHP-1 
specifically in neutrophils, which renders these cells hyperadhesive and hyper-responsive to 
ligation of β2 integrins. The only major sequela of this dysregulated neutrophil function is the 
development of chronic skin inflammation, which is prevented by neutrophil-specific genetic 
blockade of integrin signaling. Alterations in the gene encoding the SHP-1 phosphatase 
(PTPN6) have been reported in cases of human neutrophilic dermatoses [138]. Clearly, 
further work in this area is warranted.   
 
 
8.  Novel therapeutic approaches targeting neutrophils 
 
Given the wealth of new information revealing novel functions for neutrophils in 
various autoimmune and inflammatory diseases, the potential for new therapeutics is 
obvious. Perhaps the most interesting therapeutic target is neutrophil NETosis. Indeed, as 
described above, blockade of NETosis using PAD inhibitors has been successful in mouse 
models of lupus and arthritis. The PAD inhibitors may also be useful to modulate neutrophil-
mediated inflammation in other diseases such as atherosclerosis, by reducing NETosis 
[139]. Other pharmacologic approaches to inhibiting NETosis could include use of 
antimalarials; chloroquine has recently been shown to reduce NET formation in vitro [31], 
while blockade of calcium flux, through various channel blockers may also modulate 
NETosis [140]. As mentioned previously, stabilization of histone acetylation may also help 
reduce NETosis in various inflammatory diseases. Reduction of ROS by treatment with anti-
oxidants such as N-acteyl cysteine could also be effective therapeutics [141]. Studies in 
mouse models suggest that inhibition of mitochondrial ROS production may be sufficient to 
block NETosis, while avoiding all the other sequela of NADPH oxidase inhibition that have 
been observed [34]. DNAse treatment to physically degrade NETs is another approach as is 
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blockade of one of the major immune activators that is induced by NETs, namely IFNα. 
Indeed, therapeutic targeting of NETosis for treatment of autoimmunity, while avoiding 
substantial risks of treatment-related infections, is a very active area of clinical research 
[142].  
Other neutrophil-specific approaches can be envisioned such as specific targeting of 
chemokine/chemoattractant receptors on neutrophils, including BLT-1 (the receptor for LTB4) 
or CXCR1/2 (the receptors for IL-8-like chemokines) using mAb approaches. Second or third 
generation of bi-specific antibodies could be used to ensure neutrophil-specific targeting of 
these agents [143, 144]. A similar approach could be used to target cytokines made 
specifically by neutrophils, such as BAFF. Though anti-BAFF blockade using mAbs 
recognizing the soluble cytokine have had only moderate efficacy in human clinical trials, 
targeting the neutrophil site of production, may be much more effective [145, 146]. 
Combining such therapies with other antibodies, such as Rituximab that targets B-cell CD20, 
has been proposed [147]. Similar approaches could be envisioned for other neutrophil-
derived cytokines, such as IL-1β, which has been implicated in multiple autoimmune models, 
or the S100A8/9 proteins.  
Obviously, most therapeutics are based on small molecule inhibitors of specific 
enzymes. To achieve neutrophil-specific targeting with small molecules, one needs to focus 
on target enzymes that are predominately found in neutrophils. Though not restricted to 
neutrophils, there are a number of potential tyrosine kinase enzymes that are relatively 
immune cell-specific, whose therapeutic targeting has been validated in a number of murine 
autoimmune models. This includes Src-family kinases, Syk and Btk [56, 148, 149]. This is 
only a partial list; indeed, many of the inhibitors against signaling molecules which were 
developed to treat various malignancies may be “re-purposed” to treat 
autoimmune/inflammatory diseases through their action on neutrophil functions. Careful 
clinical testing will be required to identify novel disease indications for currently available 
small molecule inhibitors. 
 
 
9.  Conclusions 
A number of the mechanisms by which neutrophils contribute to autoimmune and 
inflammatory disease pathology are summarized in Figure 1. These mechanisms emphasize 
that neutrophils are involved in disease pathogenesis in many ways other than simply 
inducing tissue injury through release of proteases and ROS. Indeed, as summarized in 
Table 1 and Table 2, there are examples where neutrophil-derived mechanisms both 
exacerbate autoimmune disease as well as examples of neutrophils protecting the host from 
inflammatory tissue injury.  Clearly, neutrophils are regulatory players in the overall immune 
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response, both through direct production of cytokines/chemoattractants as well as indirect 
effects on other immune cells through agents such as MPO and ROS. It is also clear that 
neutrophils are the source of self-antigens in many autoimmune diseases. Much of this 
complexity has been revealed in studies using animal models, which will continue to improve 
as neutrophil-specific gene targeting and interventional approaches improve. In the past, 
drug development efforts have always shied away from targeting neutrophils, mainly for fear 
of severe infectious complications. Given what we know now about neutrophil contributions 
to autoimmune pathogenesis, it is possible to envision the development of agents that can 
block aspects of neutrophil function while only modestly impairing host-defense. The use of 
existing animal models, and the development of new ones, will be central to improving our 
ability to control autoimmune diseases by modulating neutrophil function.  
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Figure 1  
Cellular mechanisms by which neutrophils can drive autoimmune/inflammatory diseases, as 
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